• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Oric Pharmaceuticals, Inc. - Common Stock (NQ:ORIC)

    7.500 -0.520 (-6.48%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 5, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Oric Pharmaceuticals, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    News headline image
    ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From ORIC Pharmaceuticals
    Via GlobeNewswire
    News headline image
    ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
    From ORIC Pharmaceuticals
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates
    From ORIC Pharmaceuticals
    Via GlobeNewswire
    News headline image
    ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From ORIC Pharmaceuticals
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc. - ORIC
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From ORIC Pharmaceuticals
    Via GlobeNewswire
    Top movers analysis one hour before the close of the markets on 2026-04-01: top gainers and losers in today's session. ↗
    Via Chartmill
    Keep an eye on the top gainers and losers in Wednesday's session. ↗
    Via Chartmill
    News headline image
    What's Behind The Drop In Oric Pharmaceuticals Stock Today? ↗
    Shares of Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) are tumbling Wednesday after the company announced an update from the Phase 1b trial of rinzimetostat in combination with darolutamide in patients... 
    Via Benzinga
    These stocks are gapping in today's session ↗
    Via Chartmill
    Which stocks are moving before the opening bell on Wednesday? ↗
    Via Chartmill
    Top movers in Tuesday's after hours session ↗
    Via Chartmill
    News headline image
    ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile
    From ORIC Pharmaceuticals
    Via GlobeNewswire
    News headline image
    ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC
    Company to host a conference call and webcast on Tuesday, March 31, 2026 at 4:30 pm ET 
    From ORIC Pharmaceuticals
    Via GlobeNewswire
    News headline image
    Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. ↗
    Relay Therapeutics develops precision oncology medicines using proprietary computational modeling and strategic industry partnerships. 
    Via The Motley Fool
    News headline image
    Nextech Trims Kymera at a Recent High — think Foolishly before acting. ↗
    Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing a diversified clinical pipeline. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting
    From ORIC Pharmaceuticals
    Via GlobeNewswire
    News headline image
    BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
    U.S. stock futures lower, with Dow futures down over 1%. BETA Technologies (NYSE: BETA) fell in pre-market trading after reporting fourth-quarter results. Other stocks declining in pre-market trading... 
    Via Benzinga
    Topics Stocks
    News headline image
    ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From ORIC Pharmaceuticals
    Via GlobeNewswire
    News headline image
    ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates
    From ORIC Pharmaceuticals
    Via GlobeNewswire
    News headline image
    ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From ORIC Pharmaceuticals
    Via GlobeNewswire
    News headline image
    ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
    From ORIC Pharmaceuticals
    Via GlobeNewswire
    News headline image
    ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones
    From ORIC Pharmaceuticals
    Via GlobeNewswire
    News headline image
    ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From ORIC Pharmaceuticals
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.